ClinicalTrials.gg
CompletedNCT01185847Updated Jan 1, 2016

A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

A Phase 2 interventional study of RO5083945 and cisplatin in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 32 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-01.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 5 under way, none of them phase 3. Gemcitabine · Carcinoma, Non-Small-Cell Lung.

Enrollment
50th of 152
90 · median 53
Started
2010
with 4 others
Phase 2
109 of 169
4 open now
Registered
131st of 169
by date
Lead sponsor
4 of 169
Hoffmann-La Roche

Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, this one is the 50th largest by enrollment of the 152 interventional ones that give a count, is one of 5 that started in 2010, is one of 109 in phase 2, and was the 131st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This open label, 2-part study will evaluate the safety and efficacy of RO5083945 in combination with standard chemotherapy in patients with advanced or recurrent non-small cell lung cancer who have not received prior chemotherapy. In Part 1 patients will receive RO5083945 intravenously and standard chemotherapy (cisplatin plus either gemcitabine or pemetrexed) for up to 6 cycles of 3 weeks and then RO5083945 until disease progression. In Part 2 patients will be randomized to receive either RO5083945 in combination with standard chemotherapy or chemotherapy alone for up to 6 cycles. In the absence of disease progression, patients receiving RO503945 can continue treatment with RO5083945 as monotherapy.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/=18 years of age
  • Advanced (IIIb), (IV) or recurrent non-small cell lung cancer
  • At least 1 lesion as per criteria
  • Confirmed presence of EGFR in tumor tissue
  • performance status 0-1
  • Adequate hematological, renal and liver function

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy or treatment with another systemic anti-cancer agent
  • Radiotherapy within the last 4 weeks, except for limited field palliative radiotherapy for bone pain relief
  • Symptomatic or active
  • Recent history of poorly controlled hypertension (systolic >180mmHg or diastolic >100mmHg)
  • Requirement for > 40 mg prednisolone
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    A non-squamous

    Drug: RO5083945 · Drug: cisplatin · Drug: pemetrexed

  • Experimental
    A squamous

    Drug: RO5083945 · Drug: cisplatin · Drug: gemcitabine

  • Active comparator
    B non-squamous

    Drug: cisplatin · Drug: pemetrexed

  • Active comparator
    B squamous

    Drug: cisplatin · Drug: gemcitabine

Interventions

  • intravenously, until disease progression

  • standard treatment, up to 6 cycles

  • standard treatment, up to 6 cycles

  • standard treatment, up to 6 cycles

06

What researchers measure

Primary outcomes

  1. Part 2: Progression-free survival, according to RECIST criteria by CT/MRI

    Time frame: 23 months

  2. Part 1: Adverse event profile: adverse events, ECG, hematology, urinalysis, human anti-human antibodies (HAHA)

    Time frame: 6 months

Secondary outcomes

  1. Pharmacokinetics of RO5083945 (AUC, Cmax and Cmin) in combination with cisplatin and gemcitabine/pemetrexed

    Time frame: multiple sampling cycles 1-6 (18 weeks)

  2. Duration of response, according to RECIST criteria by CT/MRI

    Time frame: from response to disease progression

  3. Clinical benefit rate (complete response, partial response or stable disease for >/=6 weeks), according to RECIST criteria by CT/MRI

    Time frame: 23 months

  4. Overall survival

    Time frame: 23 months

  5. Overall response rate (ORR), according to RECIST criteria by CT/MRI

    Time frame: 23 months

07

Study locations

32 sites
  • Charleroi, B6000, Belgium
  • Leuven, 3000, Belgium
  • Liège, 4000, Belgium
  • Caen, 14033, France
  • Marseille, 13915, France
  • Saint Herblain, 44805, France
  • Toulouse, 31400, France
  • Bad Berka, 99437, Germany
  • Gauting, 82131, Germany
  • Grosshansdorf, 22927, Germany
  • Heidelberg, 69126, Germany
  • Köln, 51109, Germany
  • Mainz, 55131, Germany
  • Mannheim, 68167, Germany
  • Milano, Lombardia 20162, Italy
  • Milan, Lombardia 20132, Italy
  • Ancona, Marche, Italy
  • Lido Di Camaiore, Toscana 55043, Italy
  • Livorno, Toscana 57100, Italy
  • Perugia, Umbria 06156, Italy
  • Lodz, 93-509, Poland
  • Otwock, 05-400, Poland
  • Warszawa, 02-781, Poland
  • Barcelona, 08003, Spain
  • Barcelona, 08035, Spain
  • Madrid, 28040, Spain
  • Madrid, 28041, Spain
  • Madrid, 28046, Spain
  • Madrid, 28050, Spain
  • Malaga, 29010, Spain
  • Sevilla, 41013, Spain
  • London, SE1 9RT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2010
First posted
Aug 20, 2010
Start
Nov 2010
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Jan 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01185847
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 20, 2010
Start date
Nov 2010
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Jan 1, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imgatuzumab · Gemcitabine · Pemetrexed

Start the discussion